Latest Market News

Constellation Technologies broadens its Callisto Food Safety platform into new sectors and launches innovative IoT products, while managing a modest cash outflow in Q4 2025.

Key Petroleum Limited has successfully placed all remaining shortfall shares from its recent entitlement offer, securing over A$312,000 in gross proceeds. This final step closes the capital raising round initiated in May 2025.

IMEXHS Limited reported steady Q2 FY25 revenue with an 11% rise in annual recurring revenue, supported by a $2.6 million capital raise and operational advances including a major Mexican contract win.

Australian Bond Exchange Holdings (ASX, ABE) reported a stronger Q4 FY25 with participation in a landmark digital currency pilot and the launch of an innovative AUD-denominated market-linked security, alongside improved cash flow and fresh capital raises.

TerraCom reported steady coal sales for the June quarter despite softer thermal coal prices and weather disruptions, opting to withhold dividends while advancing key projects.

Victor Group Holdings delivered a positive net operating cash flow of $586k in the June 2025 quarter, driven by its cloud services and e-learning segments, while maintaining a healthy cash position and no external debt.

Alvo Minerals has progressed multiple prospects at its Palma Copper-Zinc Project in Brazil, secured $1.56 million through an entitlement offer, and expanded its mining services division, positioning itself for growth.

Swift Networks reports positive FY25 cash flow and EBITDA, secures new mining contracts, and progresses its next-generation Swift Access 2026 platform poised to accelerate growth.

Cann Group Limited delivered record production and revenue growth in Q4 FY2025, securing new funding and advancing a major debt restructuring to set the stage for profitability in FY2026.

Tasman Resources progresses exploration at Lake Torrens and Parkinson Dam projects while managing capital through a recent entitlement offer and loan repayments.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Clarity Pharmaceuticals has bolstered its cash reserves to approximately $288 million following a $203 million institutional placement, while reporting significant clinical progress across multiple copper-based radiopharmaceutical trials targeting prostate cancer and neuroendocrine tumours.